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BACKGROUND: The term “end stage” has been used to describe 
hypertrophic cardiomyopathy (HCM) with left ventricular systolic dysfunction 
(LVSD), defined as occurring when left ventricular ejection fraction is <50%. 
The prognosis of HCM-LVSD has reportedly been poor, but because of its 
relative rarity, the natural history remains incompletely characterized.
METHODS: Data from 11 high-volume HCM specialty centers making up the 
international SHaRe Registry (Sarcomeric Human Cardiomyopathy Registry) 
were used to describe the natural history of patients with HCM-LVSD. Cox 
proportional hazards models were used to identify predictors of prognosis 
and incident development.
RESULTS: From a cohort of 6793 patients with HCM, 553 (8%) met the 
criteria for HCM-LVSD. Overall, 75% of patients with HCM-LVSD experienced 
clinically relevant events, and 35% met the composite outcome (all-cause 
death [n=128], cardiac transplantation [n=55], or left ventricular assist device 
implantation [n=9]). After recognition of HCM-LVSD, the median time to 
composite outcome was 8.4 years. However, there was substantial individual 
variation in natural history. Significant predictors of the composite outcome 
included the presence of multiple pathogenic/likely pathogenic sarcomeric 
variants (hazard ratio [HR], 5.6 [95% CI, 2.3–13.5]), atrial fibrillation (HR, 2.6 
[95% CI, 1.7–3.5]), and left ventricular ejection fraction <35% (HR, 2.0 [95% 
CI, 1.3–2.8]). The incidence of new HCM-LVSD was ≈7.5% over 15 years. 
Significant predictors of developing incident HCM-LVSD included greater left 
ventricular cavity size (HR, 1.1 [95% CI, 1.0–1.3] and wall thickness (HR, 1.3 
[95% CI, 1.1–1.4]), left ventricular ejection fraction of 50% to 60% (HR, 
1.8 [95% CI, 1.2, 2.8]–2.8 [95% CI, 1.8–4.2]) at baseline evaluation, the 
presence of late gadolinium enhancement on cardiac magnetic resonance 
imaging (HR, 2.3 [95% CI, 1.0–4.9]), and the presence of a pathogenic/likely 
pathogenic sarcomeric variant, particularly in thin filament genes (HR, 1.5 
[95% CI, 1.0–2.1] and 2.5 [95% CI, 1.2–5.1], respectively).
CONCLUSIONS: HCM-LVSD affects ≈8% of patients with HCM. Although 
the natural history of HCM-LVSD was variable, 75% of patients experienced 
adverse events, including 35% experiencing a death equivalent an estimated 
median time of 8.4 years after developing systolic dysfunction. In addition to 
clinical features, genetic substrate appears to play a role in both prognosis 
(multiple sarcomeric variants) and the risk for incident development of HCM-
LVSD (thin filament variants).
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Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, with an es-timated prevalence of 1 in 500 in the adult 
population.1–3 Pathogenic variants in genes that encode 
cardiac sarcomeric proteins are responsible for causing 
disease in roughly 60% of familial and 20% to 30% of 
apparently sporadic HCM.4 Left ventricular (LV) systolic 
function is characteristically normal to hyperdynamic in 
HCM. However, prior studies have suggested that 4% 
to 9% of patients develop systolic dysfunction, defined 
by LV ejection fraction (LVEF) <50% (herein referred to 
as HCM with LV systolic dysfunction [LVSD]). This com-
plication of disease has previously been called “end-
stage” or “burnt-out” HCM.5–8 HCM-LVSD is typically 
accompanied by diffuse myocardial fibrosis, although 
LV wall thinning and cavity enlargement may also be 
present.6,9 The reported prognosis of patients with 
HCM-LVSD has been quite poor, with mortality as high 
as 11%/year.6 However, because of its relative rarity, 
the natural history remains incompletely characterized. 
There is a clear need to better understand HCM-LVSD 
to improve risk stratification and to inform clinical man-
agement. In this study, we leverage the international 
SHaRe (Sarcomeric Human Cardiomyopathy Registry),10 
analyzing data on nearly 7000 patients with HCM, to 
better describe the prevalence and natural history of 
HCM-LVSD, to identify predictors of prognosis, and to 
identify features that predict incident development of 
systolic dysfunction.
METHODS
SHaRe is an international collaborative consortium of high-
volume HCM centers that maintain longitudinal databases 
capturing phenotypic, genetic, and clinical outcomes data 
on patients with HCM and their families. The structure of the 
registry and initial findings have previously been described in 
detail.10 Briefly, definitions for phenotypic features and clini-
cal outcomes were harmonized, and site data are mapped to 
a secure, centralized data set. Historical events that occurred 
before the initial visits to SHaRe sites are carefully ascertained 
and vetted for accuracy through detailed patient history and 
medical record review. Prospective longitudinal data are 
captured by sites as they occur or during clinical encounters 
and uploaded quarterly from site databases. Institutional 
review and ethics approval were obtained in accordance 
with applicable site policies. This study analyzed data from 
1960 through March 2019 from 11 different sites around 
the world (Brigham and Women’s Hospital, Boston, MA; 
Boston Children’s Hospital, MA; University of Michigan, Ann 
Arbor; Cincinnati Children’s Hospital, OH; Yale-New Haven 
Hospital, CT; Stanford University, CA; Cardiomyopathy 
Unit, University of Florence, Italy; Erasmus Medical Center, 
Rotterdam, the Netherlands; Royal Brompton Hospital, 
London, United Kingdom; University of São Paulo, Brazil; 
University of Sydney, Australia). The data cannot be made 
available to other researchers for purposes of reproducing or 
replicating the procedure because of constraints related to 
human subjects research. Analytical methods can be made 
available on request.
Study Population
Patients were included in this study if they had at least 1 
complete echocardiographic study at a SHaRe site and a 
site-designated diagnosis of HCM, defined as unexplained 
LV hypertrophy with a maximal LV wall thickness >15 mm or 
>13 mm in members of families with HCM (or equivalent LV 
wall thickness z score in pediatric patients). Extracardiac fea-
tures, family history, and genotype were integrated to allow 
accurate and informed diagnosis by experienced clinicians. 
Genetic testing was performed at sites using different plat-
forms available over time, focusing on the 8 sarcomeric genes 
definitively associated with HCM (MYBPC3, MYH7, TNNT2, 
TNNI3, TPM1, MLY2, MYL3, and ACTC). Sites used current 
criteria11 to classify variants as pathogenic or likely pathogenic 
(denoted  SARC+; including patients with >1 pathogenic/
likely pathogenic variant), a variant of unknown signifi-
cance (denoted SARC VUS), or likely benign/benign (included 
as SARC− with patients with no clinically relevant variants 
identified on genetic testing, denoted SARC−). Sarcomeric 
variants with discordant classification among sites underwent 
additional systematic review by a subgroup of investigators 
(C.Y.H., J.S.W., S.M.D.) to adjudicate and standardize classifi-
cation. Patients were excluded if they had potentially patho-
genic variants in genes encoding nonsarcomeric proteins such 
as GLA or LAMP2, indicating the presence of metabolic or 
Clinical Perspective
What Is New?
• Left ventricular systolic dysfunction develops in 
≈8% of patients with hypertrophic cardiomyopa-
thy (HCM).From recognition of HCM with left ven-
tricular systolic dysfunction, the estimated median 
time to death, transplantation, or need for left ven-
tricular assist device is 8.4 years.
• Risk factors of poor prognosis for patients with 
HCM with left ventricular systolic dysfunction are 
multiple pathogenic/likely pathogenic sarcomeric 
variants, atrial fibrillation, and left ventricular ejec-
tion fraction <35%.
• Patients with HCM with pathogenic sarcomeric 
variants (particularly in thin filament genes), 
increased left ventricular wall thickness, left ven-
tricular dilation, and borderline low ejection frac-
tion (50%–59%) are at higher risk for developing 
HCM with left ventricular systolic dysfunction.
What Are the Clinical Implications?
• Assessing both genetic and clinical risk factors 
can improve stratification and prognostication of 
patients with HCM.Patients with left ventricular 
ejection fraction of 50% to 59% have an increased 
risk for further decline in systolic function and may 
benefit from closer follow-up.D
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storage disease or other phenocopies of HCM. Initial clinical 
characteristics represent data at first evaluation at a SHaRe 
site. All cardiac dimensions and function were based on echo-
cardiographic measurements.
Outcomes
Patients were designated as having HCM-LVSD at the first 
documentation of an echocardiographic LVEF <50% on 
a  clinically performed echocardiographic study. To identify 
predictors of prognosis in HCM-LVSD, patients were fol-
lowed from recognition of HCM-LVSD until last follow-up or 
meeting the composite outcome of all-cause mortality, car-
diac transplantation, or implantation of an LV assist device 
(LVAD). Development of atrial fibrillation and New York Heart 
Association (NYHA) functional class III/IV symptoms were also 
assessed. Analyses to identify factors associated with incident 
HCM-LVSD included genotyped patients with LVEF ≥50% and 
no history of septal reduction at or before their initial SHaRe 
visit. Patients with existing HCM-LVSD at their initial SHaRe 
evaluation were excluded from this model. Sensitivity analysis 
was performed to compare septal reduction therapies (SRTs) 
in patients diagnosed with HCM before and after January 
2000 to limit analysis to patients who were diagnosed with 
HCM and underwent procedures in the current era.
Statistical Analysis
Normally distributed data were expressed as mean±SD and 
compared with the Student t test. Nonnormally distributed 
data were expressed as median and interquartile range and 
compared with the Wilcoxon rank-sum test. Differences in 
categorical variables were calculated with the χ2 test. The 
Kaplan-Meier method with log-rank test for significance was 
used to estimate the cumulative incidence and time to event 
of the end points of interest, starting from the time of the ini-
tial visit to a SHaRe site. To adjust for baseline characteristics, 
Cox proportional hazards models were developed, requiring 
a minimum of 10 events (incident HCM-LVSD or composite 
outcome) per covariate included.12 Results of Cox regressions 
were reported as adjusted hazard ratios (HRs) with 95% CIs. 
Analyses were depicted in forest plots, and values of P˂0.05 
were considered statistically significant. If patients were miss-
ing echocardiographic measures at the first SHaRe evaluation, 
data were imputed from subsequent echocardiographic stud-
ies if the echocardiogram was performed before the develop-
ment of HCM-LVSD. Patients missing key echocardiographic 
data in all of their studies in SHaRe were omitted from Cox 
regression models. R version 3.5.2 was used for all analyses.
RESULTS
Prevalence and Clinical Features of HCM-
LVSD
Of 7594 patients with HCM receiving care at a SHaRe 
site between 1960 and March 2019, 6793 met inclu-
sion criteria and were analyzed in this study. HCM-LVSD 
was present in 553 patients (8.1% of the cohort; Ta-
ble 1), including 203 who already had LVEF <50% at 
initial SHaRe evaluation (prevalent HCM-LVSD) and 350 
who developed HCM-LVSD during follow-up (incident 
HCM-LVSD). Men represented 62.2% of the overall co-
hort, and there was no significant difference in the pro-
portion of male and female patients with and without 
LVSD. Collectively, patients with HCM-LVSD (incident 
and prevalent cases combined) were ≈6.5 years young-
er at diagnosis than patients with HCM without systolic 
dysfunction (35.6 years versus 42.1 years; P<0.001) 
with no significant difference between the prevalent 
and incident HCM-LVSD groups. It is notable that 
follow-up was longer in patients with incident HCM-
LVSD compared with patients without systolic dysfunc-
tion (median, 9.8 years versus 2.9 years; P<0.001) and 
patients with prevalent HCM-LVSD (median, 3.2 years; 
P<0.001). In a comparison of genotyped patients 
(n=4224), patients with HCM-LVSD were more likely to 
have sarcomeric disease than patients without systolic 
dysfunction (241 of 394 [61.2%] versus 1767 of 3830 
[46.1%]; P<0.001).
As Table 1 shows, patients with incident HCM-LVSD 
had greater maximal LV wall thickness (20±7 mm ver-
sus 18±6 mm; P<0.001), LV diastolic diameter (45±8 
mm versus 44±7 mm; P<0.001), and left atrial diam-
eter (46±1 mm versus 42±1 mm; P<0.001) at initial 
SHaRe evaluation compared with patients with HCM 
who did not develop systolic dysfunction. Although 
patients with incident HCM-LVSD did not have systolic 
dysfunction at their initial visit, LVEF was significantly 
lower than in patients with HCM who did not develop 
systolic dysfunction (61±7% versus 66±8%; P<0.001). 
Patients with incident HCM-LVSD were also more likely 
to have NYHA class III/IV symptoms at the initial SHaRe 
visit (11.1% versus 7.6%; P=0.025) but less likely to 
have obstructive physiology (defined as LV outflow tract 
>30 mm Hg; 27.8% versus 38.8%; P<0.001).
Raw counts and HRs of all events experienced by 
patients with HCM-LVSD and HCM without LVSD are 
presented in Table  2. HRs are adjusted for age, sex, 
and follow-up time from the initial SHaRe evaluation. 
Patients with HCM-LVSD had a markedly higher preva-
lence of cardiac transplantation (11.4% versus 0.7%) 
and LVAD implantation (1.6% versus 0.1%; P<0.001 
for all comparisons). Patients with HCM-LVSD were 
more likely to experience all-cause death (25.0% ver-
sus 6.7%), implantable cardioverter-defibrillator (ICD) 
implantation (54.4% versus 21.6%), and appropriate 
ICD firing (25.2% versus 12.1%; P<0.001). Atrial fi-
brillation (49.3% versus 20.9%) and stroke (8.4% ver-
sus 2.3%) were also more common in patients with 
HCM-LVSD.
A greater proportion of patients with HCM-LVSD 
underwent SRT compared with patients without LVSD 
(27.3% versus 17.5%; P<0.001; Table  3). The major-
ity of procedures were myectomy (78% of SRT proce-
dures). The proportion undergoing alcohol septal abla-
tion did not differ between groups (4.0% versus 3.2%; 
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P=0.34), but patients with HCM-LVSD were more likely 
to have had both myectomy and alcohol ablation per-
formed (1.6% versus 0.6%; P<0.001).
Natural History of HCM-LVSD
We characterized natural history by focusing on our 
cohort of 553 patients with HCM-LVSD. As Table 4 
shows, patients with HCM-LVSD were a mean age 
of 35.6±19.2 years when diagnosed with HCM and 
50.3±17.9 years when recognized to have LVEF <50%. 
The mean LVEF at presentation with HCM-LVSD was 
40±8%, and 27.1% of patients had an LVEF <35% at 
presentation. Thirty percent (165 of 553) had NYHA 
class III/IV symptoms at presentation with HCM-LVSD.
Table  5 lists clinical events associated with the to-
tal HCM-LVSD cohort, both before developing systolic 
dysfunction and during follow-up. Overall, 74.7% of 
patients with HCM-LVSD experienced clinically relevant 
events. At the time of HCM-LVSD presentation, 41.6% 
of patients had atrial fibrillation and  39.1% had an ICD. 
During follow-up, 192 patients (34.7%) with HCM-LVSD 
met the composite outcome (all-cause death [n=128], 
cardiac transplantation [n=55], or LVAD implantation 
Table 1. Clinical Characteristics of Patients at the Initial SHaRe Evaluation
Demographics at Initial 
Evaluation
Total
(n=6793)
HCM Without 
LVSD (n=6240)
Prevalent HCM-
LVSD (n=203)
Incident HCM-
LVSD (n=350)
P Value,
HCM Without LVSD 
vs Incident HCM-
LVSD
P Value,Incident 
HCM-LVSD vs 
Prevalent HCM-
LVSD
Male, n (%) 4226 (62.2) 3875 (62.1) 124 (61.1) 227 (64.9) 0.328 0.426
Age at diagnosis with HCM, 
mean±SD, y
41.5±20.4 42.1±20.4 36.5±19.5 35.1±19.0 <0.001 0.426
Age at initial SHaRe evaluation, 
mean±SD, y
46.4±19.7 46.5±19.8 49.3±17.5 43.2 (18.4) 0.002 <0.001
Follow-up, median (IQR), y 3.2 (0.6–7.6) 2.9 (0.5–7.1) 3.2 (0.5–7.0) 9.8 (5.9–14.5) <0.001 <0.001
NYHA III/IV at initial SHaRe 
evaluation, n (%)
520 (8.1) 447 (7.6) 36 (18.5) 37 (11.1) 0.025 0.027
Family proband, n (%) 6159 (91.4) 5657 (91.4) 184 (91.5) 318 (91.4) 1.000 1.000
Genetics (n=4224 with genetic 
testing), n (%)
    <0.001* 0.557*
  SARC−* 1839 (45.5) 1716 (44.8) 43 (34.7) 80 (29.6)   
  SARC VUS* 377 (8.9) 347 (9.1) 8 (6.5) 22 (8.1)   
  SARC+* 2008 (47.5) 1767 (46.1) 73 (58.9) 168 (62.2)   
   Thick filament variant† 1748 (87.1) 1545 (87.4) 57 (78.1) 146 (86.9)   
   Thin filament variant† 192 (9.6) 167 (9.5) 12 (16.4) 13 (7.7)   
   Multiple P/LP variants† 68 (3.4) 55 (3.1) 4 (5.5) 9 (5.3)   
     No genetic testing 2569 (37.8) 2410 (38.6) 79 (38.9) 80 (22.9)   
Race, n (%)     0.066 0.718
  Black 236 (3.5) 224 (3.6) 6 (3.0) 6 (1.7)   
  White 5672 (83.5) 5188 (83.1) 174 (85.7) 310 (88.6)   
  Other or not reported 885 (13.0) 828 (13.3) 23 (11.3) 34 (9.7)   
Initial echocardiographic parameters
  Maximal LV wall thickness, 
mean±SD, mm
18±6 18±6 16±5 20±7 <0.001 <0.001
  LVEF, mean±SD, % 65.±1 66±8 38±9 61±7 <0.001 <0.001
  Obstruction, LVOT >30 mm Hg, 
n (%)
1790 (37.6) 1708 (38.8) 8 (8.5) 74 (27.8) <0.001 <0.001
  LV diastolic diameter, mean±SD, 
mm
44±7 44±7 51±9 45±8 <0.001 <0.001
  Left atrial diameter, mean±SD, 
mm
42±1 42±1 51±1 46±1 <0.001 <0.001
HCM indicates hypertrophic cardiomyopathy; IQR, interquartile range; LV, left ventricular; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow 
tract; LVSD, left ventricular systolic dysfunction; NYHA, New York Heart Association; P/LP, pathogenic/likely pathogenic sarcomeric variants; SARC VUS, a variant of 
unknown significance in a sarcomeric gene; SARC+, ≥1 pathogenic/likely pathogenic variant; SARC−, no clinically relevant sarcomeric variants identified on genetic 
testing; and SHaRe, Sarcomeric Human Cardiomyopathy Registry.
*Percentages and P values represent patients with genetic testing.
†Percentages represent SARC+ patients.
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[n=9]). In addition, 25% of those with an ICD received an 
appropriate therapy (40 of 186 [22%] patients with LVEF 
<35% and 36 of 397 [9%] patients with LVEF >35%; 
P<0.001). The estimated median time from recogni-
tion of HCM-LVSD to composite outcome was 8.4 years 
(95% CI, 7.4–9.3; Figure 1A). Assessing death alone as 
an outcome showed that 138 patients (25%) with HCM-
LVSD died, including 10 patients who died after cardiac 
transplantation or LVAD implantation. The median time 
to death was 11.4 years (95% CI, 9.3–14.9 years) after 
the development of systolic dysfunction. Patients with 
HCM-LVSD at the initial evaluation had a prognosis from 
the time of HCM-LVSD similar to those who developed 
incident HCM-LVSD during follow-up (data not shown).
Clinical course varied substantially from patient to 
patient. As Figure  2 illustrates, many patients with 
HCM-LVSD across a broad spectrum of ages do not ex-
perience the composite outcome, whereas many others 
at similar ages and duration of HCM-LVSD experienced 
serious outcomes.
Predictors of Prognosis in HCM-LVSD
Among the 553 patients with HCM-LVSD, carrying a 
pathogenic sarcomeric variant (P=0.039), concomitant 
atrial fibrillation (P<0.001), and severe LV dysfunction at 
recognition of HCM-LVSD (LVEF <35%, P<0.001) were 
each associated with a higher likelihood and earlier oc-
currence of the composite outcome in univariate analyses 
(Figure 1B-D). To identify independent predictors of poor 
prognosis, we performed a multivariate analysis for 394 
of the 553 patients with HCM-LVSD who were genotyped 
(Figure  3). Of this genotyped cohort, 136 (34.5%) ex-
perienced the composite outcome. Atrial fibrillation (HR 
2.6 [95% CI, 1.8–3.8]) and LVEF <35% at recognition of 
HCM-LVSD (HR 2.0 [95% CI, 1.4–2.8]) remained indepen-
dent predictors in this model. A single sarcomere gene 
mutation was not an independent predictor, suggesting 
that mutation status covaries with atrial fibrillation or LVEF 
<35%. However, patients with multiple pathogenic/likely 
pathogenic sarcomeric variants had the highest risk for the 
composite outcome (HR, 5.6 [95% CI, 2.4–13.3]) even af-
ter adjustment for LVEF <35% and atrial fibrillation. Age 
at diagnosis of HCM-LVSD had a modest effect (HR 1.1 
[95% CI, 1.0–1.1] per 5-year increment). Sex, NYHA class 
III/IV at HCM-LVSD diagnosis, and prior SRT were not inde-
pendently predictive of the composite outcome.
Incident Development of HCM-LVSD
A cohort of 5905 patients with longitudinal data and 
LVEF >50% at the initial evaluation was available to 
Table 2. Comparison of Events in Patients With and Without LVSD
Events at Any Time
Total
(n=6793), n (%)
HCM Without LVSD
(n=6240), n (%)
HCM-LVSD
(n=553), n (%)
Adjusted HR  
(95% CI)* P Value
NYHA class III/IV 1121 (16.5) 922 (14.8) 199 (37.3) 2.0 (1.7–2.4) <0.001
All-cause death 554 (8.2) 416 (6.7) 138 (25.0) 1.8 (1.5–2.2) <0.001
Cardiac transplantation 110 (1.6) 46 (0.7) 64 (11.6) 11.0 (7.5–16.2) <0.001
LVAD implantation 15 (0.3) 4 (0.1) 11 (2.0) 26.5 (8.2–85.7) <0.001
Sudden cardiac death 90 (1.4) 70 (1.2) 20 (3.9) 3.9 (2.4–6.3) <0.001
ICD implantation 1646 (24.2) 1345 (21.6) 301 (54.4) 2.2 (1.9–2.5) <0.001
  Appropriate ICD therapy 239 (14.5) 163 (12.1) 76 (25.2) 1.6 (1.4–1.8) <0.001
Atrial fibrillation 1494 (23.2) 1229 (20.9) 265 (49.3) 2.1 (1.8–2.4) <0.001
Stroke 116 (2.8) 88 (2.3) 28 (8.4) 2.5 (1.9–3.3) <0.001
HR indicates hazard ratio; ICD, implantable cardioverter-defibrillator; LVAD, left ventricular assist device; LVSD, left ventricular systolic dysfunction; NYHA, New 
York Heart Association; and SHaRe, Sarcomeric Human Cardiomyopathy Registry.
*Based on a Cox proportional hazards model following patients from initial SHaRe evaluation, adjusted for age, sex, and follow-up time. HR >1 represents an 
increased risk observed in patients with hypertrophic cardiomyopathy with LVSD.
Table 3. Comparison of Patients With and Without LVSD Who Underwent Invasive SRT
SRT Total (n=6793) HCM Without LVSD (n=6240) HCM-LVSD(n=553) P Value
SRT before initial SHaRe evaluation 220 (3.2) 167 (2.7) 53 (9.9) <0.001
SRT before developing HCM-LVSD Not applicable Not applicable 138 (25.3) Not applicable
SRT, any time, n (%) 1221 (18.0) 1070 (17.5) 151 (27.3) <0.001
  Myectomy, any time 951 (14.0) 831 (13.3) 120 (21.7) <0.001
  Alcohol ablation, any time 223 (3.3) 201 (3.2) 22 (4.0) 0.338
  Both performed, any time 47 (0.7) 38 (0.6) 9 (1.6) 0.006
HCM indicates hypertrophic cardiomyopathy; LVSD, left ventricular systolic dysfunction; SHaRe, Sarcomeric Human Cardiomyopathy Registry; and SRT, septal 
reduction therapy.
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analyze incident development of HCM-LVSD. Of those, 
350 (5.9%) developed HCM-LVSD during follow-up. 
The estimated incidence rates were 0.5%/y from ini-
tial evaluation, 1.7% (95% CI, 1.4%–2.2%) at 5 years, 
4.5% (3.8%–5.3%) at 10 years, and 7.5% (6.5%–
8.6%) at 15 years after the initial SHaRe visit (Figure 4).
A Cox proportional hazards model was performed 
to identify predictors of developing HCM-LVSD. Of the 
5905 patients with available follow-up, 3524 had ge-
netic data available and no history of SRT at initial eval-
uation. Complete echocardiographic data were avail-
able in 2627 of those, and in 189 patients, data were 
imputed with a median time of 87 days (interquartile 
range, 39–380 days) between the initial evaluation and 
echocardiography. Hence, the model was based on a 
cohort of 2816 patients with HCM, with 170 outcomes 
of incident HCM-LVSD (Figure 5). Greater LV cavity size, 
greater LV wall thickness, and the presence of a patho-
genic/likely pathogenic sarcomeric variant were associ-
ated with increased risk of incident HCM-LVSD, with 
HRs ranging from 1.2 to 1.5. The presence of a variant 
in a thin filament gene (TNNT2, TNNI3, TPM1, ACTC) 
was associated with an HR of 2.5 (95% CI, 1.2–5.1). 
Borderline LVSD at the initial SHaRe evaluation was as-
sociated with a higher risk of incident HCM-LVSD (LVEF, 
55%–59%: HR, 1.8 [95% CI, 1.2–2.8]; LVEF 50%–
54%: HR, 2.8 [95% CI, 1.8–4.2]), likely identifying pa-
tients with incipient HCM-LVSD remodeling at presen-
tation. In patients with a baseline LVEF between 50% 
and 59% who later developed HCM-LVSD, the median 
time to onset of HCM-LVSD was 3.4 years (2.32–4.23 
years) if LVEF was 55% to 59% and 2.2 years (1.80–3.2 
years) if LVEF was 50% to 54%.
Although atrial fibrillation was a predictor of progno-
sis and was more frequently seen in patients with HCM-
LVSD (11.3% versus 4.3%), it was not an independent 
risk predictor for the development of incident HCM-LVSD 
remodeling (HR, 1.1 [95% CI, 0.8–1.5]). Patients with 
obstructive physiology (maximal LV outflow tract gradi-
ent >30 mm Hg) were less likely to develop HCM-LVSD 
(HR, 0.6 [95% CI, 0.4–0.9]), suggesting that obstructive 
physiology was not driving the development of systolic 
dysfunction in the majority of patients with HCM-LVSD.
A full list of multiple pathogenic/like pathogenic 
sarcomeric variants is provided in Table I in the Data 
Supplement. Although information about medication 
use is not fully captured in SHaRe, in an assessment 
of the subset of patients with documented medication 
use (2300 of 2816 for the model predicting incident 
risk and 289 of 394 for the prognosis model), neither 
Table 4. Clinical Characteristics at Time of Presentation With HCM-
LVSD
Demographics at HCM-LVSD Presentation HCM-LVSD (n=553)
Male, n (%) 351 (63.5)
Age at diagnosis of HCM, mean±SD, y 35.6±19.2
Age at developing HCM-LVSD, mean±SD, y 50.4±17.9
Follow-up to composite/last visit, median 
(IQR), y
2.6 (0.5–5.9)
NYHA class III/IV at presentation with HCM-
LVSD, n (%)
165 (29.8)
Atrial fibrillation at presentation with HCM-
LVSD, n (%)
230 (42.8)
Genetics, n (%)
  SARC−* 121 (30.7)
  SARC VUS* 30 (7.6)
  SARC+* 243 (61.7)
  No genetic testing 159 (28.8)
Echocardiographic measures at HCM-LVSD presentation
Maximal LVWT, mean±SD, mm 17±6
LVEF, mean±SD, % 40±8
LVEF <35%, n (%) 150 (27.1)
Obstruction, peak gradient >30 mm Hg, n (%) 38 (11)
LV diastolic diameter, mean±SD, mm 50±9
Left atrial diameter, mean±SD, mm 49±1
HCM indicates hypertrophic cardiomyopathy; IQR, interquartile range; LV, 
left ventricular; LVEF, left ventricular ejection fraction; LVSD, left ventricular 
systolic dysfunction; LVWT, left ventricular wall thickness; NYHA, New 
York Heart Association; SARC VUS, a variant of unknown significance in a 
sarcomeric gene; SARC+, ≥1 pathogenic/likely pathogenic variant; SARC−, no 
clinically relevant sarcomeric variants identified on genetic testing; and SHaRe, 
Sarcomeric Human Cardiomyopathy Registry.
*Percentages and P values represent patients with genetic testing.
Table 5. Overview of Adverse Events at Time of HCM-LVSD and at 
Any Time in Patients With HCM-LVSD
Events Total (n=553)
Events before developing HCM-LVSD, n (%)
  ICD implanted 216 (39.1)
   Appropriate ICD firing 41 (19.0)
  Atrial fibrillation 230 (41.6)
  Stroke 20 (6.0)
Events at any time, n (%)
  Clinically relevant events* 413 (74.7)
  ICD implanted 301 (54.4)
   Appropriate ICD firing 76 (25.2)
  Atrial fibrillation 265 (49.6)
  Stroke 28 (8.4)
  LVEF <35% 186 (34.1)
  Composite outcome 192 (34.7)
   Death 128 (23.1)
   Transplantation 55 (9.9)
   LVAD 9 (1.6)
HCM indicates hypertrophic cardiomyopathy; ICD, implantable cardioverter-
defibrillator; LVAD, left ventricular assist device; LVEF, left ventricular ejection 
fraction; and LVSD, left ventricular systolic dysfunction.
*Clinically relevant events include New York Heart Association class III/IV 
functional class, atrial fibrillation, LVEF <35%, appropriate ICD firing, or death/
transplantation/LVAD implantation during follow-up.
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β-blocker nor calcium channel blocker use had a signifi-
cant association with risk for developing incident HCM-
LVSD or prognosis with HCM-LVSD once developed.
Cardiac magnetic resonance studies were avail-
able in a subset of 2751 patients (HCM without LVSD, 
n=2590; incident HCM-LVSD, n=105; prevalent HCM-
LVSD, n=56; Table II in the Data Supplement). Late 
gadolinium enhancement (LGE) was more prevalent in 
combined patients with HCM-LVSD compared with pa-
tients without LVSD (85.6% versus 69.5%; P<0.001). 
In a Cox regression model adjusted for genotype, age 
at diagnosis, cardiac magnetic resonance LVEF, and sex, 
the presence of LGE was associated with an HR of 2.3 
(95% CI, 1.0–4.9; P=0.039) for developing incident 
HCM-LVSD.
Impact of SRT
Given the observation of a higher prevalence of SRT in 
patients with HCM-LVSD, we included SRT in the model 
Figure 1. Kaplan-Meier curves for reaching the composite outcome from the time of diagnosis of hypertrophic cardiomyopathy with left ventricular 
systolic dysfunction (HCM-LVSD).
A, The estimated median time to occurrence of the composite outcome is 8.4 years (95% CI, 7.4–9.3 years). Patients with (B) pathogenic sarcomeric variants 
(SARC+), (C) atrial fibrillation, or (D) left ventricular ejection fraction (LVEF) <35% at HCM-LVSD diagnosis all have worse outcomes. LVAD indicates left ventricular 
assist device; SARC−, no clinically relevant sarcomeric variants; and Tx, cardiac transplantation.
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assessing incident development of HCM-LVSD  (Figure 
5). An increased risk for developing incident HCM-LVSD 
was seen in patients who previously had a myectomy 
(n=40 of 465; HR, 2.7 [95% CI, 1.8–4.0]) or alcohol 
ablation (n=10 of 80; HR, 2.6 [95% CI, 1.3–5.2]). Fur-
ther analyses were then pursued to better characterize 
the association between SRT and incident development 
of systolic dysfunction. Overall, 1221 patients in SHaRe 
underwent SRT, of whom 138 (11.4%) developed in-
cident HCM-LVSD. These 138 patients were a mean 
43±18 years of age at SRT and developed HCM-LVSD a 
median of 5.6 years (3.9–8.6 years) after SRT.
A sensitivity analysis was performed that excluded 
patients who underwent SRT before the year 2000 
(n=8) to limit analyses to patients whose procedures 
were performed in the current era. Results were similar 
to the full model (HR for SRT, 2.4 [95% CI, 1.7–3.6]), 
suggesting that the association between HCM-LVSD 
and myectomy was not driven primarily by patients 
who underwent procedures in the remote past. In addi-
tion, adjusting for participating site did not change the 
estimated risk (data not shown).
We compared baseline clinical characteristics be-
tween patients with HCM-LVSD who did and those 
who did not undergo SRT. Patients with HCM-LVSD 
with prior SRT were similar in age, sex, sarcomeric vari-
ant status, and presenting LV wall thickness and LV 
cavity size, but they had larger left atrial diameter and 
greater LVEF at baseline evaluation (Table III in the Data 
Supplement). Patients with HCM-LVSD with prior SRT 
were also more likely to have NYHA class III/IV symp-
toms at presentation with HCM-LVSD.
We postulated that the development of HCM-LVSD 
after myectomy could be the result of procedure-
related left bundle-branch block, leading to a mild to 
moderate reduction in LVEF (LVEF, 35%–49%) but no 
other clinical sequelae (no atrial fibrillation, appropriate 
ICD therapy, or NYHA class III/IV symptoms, denoted 
uncomplicated HCM-LVSD). No significant difference in 
the proportion of uncomplicated HCM-LVSD was found 
between patients with and those without a history of 
SRT (22 of 105 [20.9%] versus 105 of 402 [26.1%]; 
P=0.31), suggesting that systolic dysfunction in patients 
with prior myectomy is not purely a reflection of other-
wise inconsequential bundle-branch block.
Once HCM-LVSD developed, the natural history in 
patients with prior SRT was not significantly different 
from that in patients without prior SRT (Table IV in the 
Figure 2. The natural history of hypertrophic cardiomyopathy with left ventricular systolic dysfunction (HCM-LVSD) is variable.
Individual-level events are shown in 553 patients with HCM-LVSD from the time of presentation with HCM-LVSD to the time of event or last visit. The x axis rep-
resents the patient’s age at diagnosis of HCM-LVSD; the y axis represents years until death (red), cardiac transplantation (blue), left ventricular assist device (LVAD) 
implantation (purple), or last visit (green). Age at event or last visit is shown above mark for a limited number of patients.
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Data Supplement). Among patients with HCM-LVSD 
with prior SRT, 26.8% developed LVEF <35% (versus 
36.5% without prior SRT; P=0.051). Patients with prior 
SRT were more likely to have an ICD implanted but less 
likely to have appropriate firing. No significant differ-
ences were found for death, need for cardiac transplan-
tation, LVAD, or atrial fibrillation between patients with 
HCM-LVSD with and those without prior SRT.
DISCUSSION
This study leverages a large, international cohort to bet-
ter characterize the prevalence and natural history of 
systolic dysfunction in HCM. The major findings are the 
following: First, ≈8% of patients with HCM develop sys-
tolic dysfunction with LVEF <50% (7.5% incidence over 
15 years). Second, the natural history of HCM-LVSD was 
variable, but ≈75% of patients experienced clinically 
relevant adverse events, including 35% experiencing 
death, cardiac transplantation, or LVAD implantation 
an estimated median of 8.4 years after developing sys-
tolic dysfunction. Third, atrial fibrillation, LVEF <35%, 
and the presence of multiple sarcomeric variants were 
independently associated with poor prognosis. Last, 
sarcomeric variants (particularly in thin filament genes), 
borderline low baseline LVEF (50%–60%), and LGE on 
cardiac magnetic resonance were independently associ-
ated with incident development of HCM-LVSD.
Prevalence and Prognosis of HCM-LVSD
Earlier, smaller studies on HCM-LVSD (n=20–156) have 
reported a prevalence ranging from 4% to 9% and a 
malignant natural history, with ≈60% of patients with 
HCM-LVSD experiencing death or cardiac transplanta-
tion over a mean time of only 2.7 to 5 years from rec-
ognition of systolic dysfunction.6–8,13–15
In our cohort of 6793 patients with HCM with a me-
dian follow-up of >3 years at HCM specialty centers, 553 
developed systolic dysfunction, representing a preva-
lence of 8.1%. Our results confirm that systolic dysfunc-
tion confers adverse outcomes. Seventy-five percent of 
patients with HCM-LVSD experienced adverse sequelae, 
and they were at least twice as likely as patients without 
systolic dysfunction to have NYHA class III/IV symptoms, 
appropriate ICD therapy, atrial fibrillation, and stroke. 
One-third of patients with HCM-LVSD developed severe 
Figure 3. Forest plot depicting risk predictors for developing the composite outcome of all-cause mortality, cardiac transplantation (Tx), or left 
ventricular assist device (VAD) implantation in 394 genotyped patients with hypertrophic cardiomyopathy with left ventricular systolic dysfunction 
(HCM-LVSD) experiencing 136 composite events.
Unadjusted number of events per variable is shown in the second column. Hazard ratios are adjusted for all included risk factors. The diamond symbol in the 
cohort with ≥1 pathogenic/likely pathogenic variant (SARC+) represents the composite effect of thin filament, thick filament, and multiple pathogenic/likely patho-
genic (P/LP) sarcomere variants. LVEF indicates left ventricular ejection fraction; LVIDd, left ventricular diastolic diameter; NYHA, New York Heart Association; ref, 
referent; SARC−, no clinically relevant sarcomere variants identified on genetic testing; and SARC VUS, a variant of unknown significance in a sarcomere gene.
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LVSD (LVEF <35%), and 35% experienced a death equiv-
alent as reflected by the composite outcome of death, 
cardiac transplantation, or LVAD implantation. Com-
pared with patients with HCM without systolic dysfunc-
tion, mortality during follow-up was >2-fold higher in 
patients with HCM-LVSD; the need for cardiac transplan-
tation or LVAD was >11- and 26-fold higher, respectively. 
However, our findings indicate that the time frame is less 
precipitous for most individuals with HCM-LVSD than 
previously described. On average, systolic dysfunction 
developed a median of 15 years after initial diagnosis of 
HCM. The median time to death, cardiac transplantation, 
or LVAD implantation was 8.4 years after recognition of 
systolic dysfunction and 11.4 years to death alone. Atrial 
fibrillation (HR, 2.6 [95% CI, 1.7–3.8]), LVEF <35% (HR, 
2.0 [95% CI, 1.3–2.8]), and the presence of multiple 
pathogenic sarcomeric variants (HR, 5.6 [95% CI, 2.1–
13.5]) were independent predictors of poor prognosis, 
as assessed by the composite outcome of death, cardiac 
transplantation, or LVAD implantation.
Moreover, the experience of patients with HCM-
LVSD was quite broad, with many free from serious 
events for many years after the initial decline in LVEF 
was documented. Thus, end stage, the previously used 
nomenclature, does not accurately reflect the major-
ity of patients with HCM-LVSD. Further investigation is 
needed to more fully understand this heterogeneity and 
to characterize the underlying factors that drive pro-
gressive adverse remodeling associated with decreased 
LV systolic function in HCM.
Incident Development of Systolic 
Dysfunction
A multivariable regression model identified sarcomeric 
variants overall (HR, 1.5 [95% CI, 1.0–2.1]) and thin fil-
ament variants in particular (HR, 2.5 [95% CI, 1.2–5.1]), 
LVEF 50% to 60% (HR, 1.8–2.8), and greater LV wall 
thickness (HR ,1.3 [95% CI, 1.1–1.4] per 5-mm incre-
ment) as independent predictors for developing systolic 
dysfunction. The transition phase of an LVEF 50% to 
59% was described by Olivotto et al16 in 2010. They 
also identified a greater extent of myocardial fibrosis as-
sociated with declining LVEF.16 Similarly, our study iden-
tified the presence of late gadolinium and LVEF of 50% 
to 60% as independent predictors for incident systolic 
dysfunction. Although this LVEF would be considered 
within normal range for other populations, it appears 
to identify patients with HCM with a nearly 3-fold in-
creased risk of developing HCM-LVSD who would likely 
benefit from closer management.
Our data identified a potential association between 
invasive SRT and future development of HCM-LVSD. 
This signal (HR >2.6 for surgical myectomy and alco-
hol ablation) persisted even after considering LV mor-
phology, function, and obstructive physiology before 
the procedure, atrial fibrillation, participating site, and 
limiting the analysis to procedures performed in the 
current era (since 2000). In our cohort, HCM-LVSD 
developed in 11% of patients who underwent SRT 
≈6 years after the procedure was performed. Patients 
with HCM-LVSD who underwent prior SRT were more 
Figure 4. Time from initial evaluation to 
developing incident hypertrophic cardio-
myopathy with left ventricular systolic 
dysfunction (HCM-LVSD).
Rates of developing incident HCM-LVSD were 
1.7% (95% CI, 1.4–2.2) at 5 years, 4.5% 
(95% CI, 3.8–5.3) at 10 years, and 7.5% (95% 
CI, 6.5–8.6) at 15 years. SHaRe indicates Sarco-
meric Human Cardiomyopathy Registry.
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likely to have an ICD implanted than those without 
prior SRT, presumably related to procedure-associated 
conduction block, but appropriate ICD therapies did 
not differ significantly. Prognosis and clinical outcomes 
appeared similar in patients with HCM-LVSD with and 
without prior SRT.
Septal reduction therapies have been studied ex-
tensively for safety and efficacy of symptom relief. In 
particular, surgical myectomy has been shown to be 
associated with low morbidity and mortality in expe-
rienced centers such as SHaRe sites.17–19 SRT plays an 
important role in the clinical management of HCM, 
providing highly effective relief of symptoms resulting 
from obstructive physiology. However, prior studies on 
SRT were not designed to identify a potential associa-
tion between myectomy and future development of 
HCM-LVSD. Thus, they would not have captured the 
development of systolic dysfunction or death-equiva-
lent outcomes of cardiac transplantation or LVAD im-
plantation (30 patients in our cohort). Nonetheless, 2 
smaller studies also identified an increased risk of 
developing impaired LV function after SRT20 and em-
phasized that the duration of follow-up needs to be 
relatively long, at least 8 to 10 years, to capture this 
adverse remodeling.21 This time frame is supported 
by our current findings. Similarly, all but 1 published 
study focusing on HCM-LVSD systematically excluded 
patients who underwent SRT.5,13,16 The study by Harris 
et al6 included 89 patients with a myectomy, 7 (8%) of 
whom developed HCM-LVSD, compared with 3% of 
patients who did not undergo myectomy. A value of 
P=0.84 was reported, without adjustment for age, sex, 
time to event, or disease severity.6
We caution that our findings reflect a relatively small 
number of patients who underwent SRT before develop-
ing HCM-LVSD. Although potential causal mechanisms 
underlying this association cannot be inferred from this 
retrospective analysis, we have considered several pos-
sibilities that could be explored in future studies. First, 
we speculate that intraventricular conduction delay/
dyssynchrony related to the procedure may play a role, 
in which case early resynchronization therapy might be 
Figure 5. Forest plot depicting risk predictors for developing incident hypertrophic cardiomyopathy with left ventricular systolic dysfunction 
(HCM-LVSD).
Unadjusted number of events per variable is shown in second column. Cox proportional hazards model is based on 2816 patients, of whom170 developed inci-
dent HCM-LVSD. Hazard ratios are adjusted for all included risk factors. The diamond symbol in the cohort with ≥1 pathogenic/likely pathogenic variant (SARC+) 
represents the composite effect of thin filament, thick filament, and multiple pathogenic/likely pathogenic (P/LP) sarcomeric variants. LVEF indicates left ventricular 
ejection fraction; LVIDd, left ventricular diastolic diameter; ref, referent; SARC−, no clinically relevant sarcomere variants identified on genetic testing; SARC VUS, a 
variant of unknown significance in a sarcomere gene; and SRT, septal reduction therapy.
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considered in certain patients (eg, LVEF <55%). Second, 
the HCM-LVSD cohort with SRT may be confounded by 
some degree of selection bias because these patients 
may have been referred for a higher degree of symp-
toms as a result of more severe underlying adverse re-
modeling. Last, it is possible that preexisting pressure 
overload could lead to more advanced remodeling in a 
subset of patients, despite adequate relief of LV outflow 
tract obstruction. Our data suggest that patients un-
dergoing SRT require longitudinal monitoring of cardiac 
function after the procedure, particularly younger pa-
tients with sarcomere gene mutations. Further study is 
needed to better characterize the associations between 
SRT and HCM-LVSD, to elucidate broader effects of SRT 
on long-term cardiac remodeling, and to fully under-
stand the clinical implications.
Limitations
Although SHaRe incorporates curated, longitudinal 
data, it is subject to the limitations inherent to all ob-
servational and partially retrospective registry-based 
studies. Cardiac magnetic resonance data are derived 
from site-based clinical reports, which do not routinely 
capture data on quantification and location of LGE. On 
the basis of recent literature, we anticipate that <4% 
of patients with HCM will have extensive LGE (>15% 
involvement).22 Because participating sites are high-
volume HCM specialty centers, our study could be in-
fluenced by referral bias, resulting in an overestimation 
of the prevalence of HCM-LVSD and adverse prognosis 
of HCM-LVSD. Conversely, the registry is also subject 
to survival bias because patients must survive until be-
ing seen at a SHaRe site. It is notable that the patients 
with incident systolic dysfunction had longer follow-up 
compared with the group who did not develop systolic 
dysfunction, suggesting that the prevalence is likely 
to be higher with longer follow-up. Continued multi-
center study in adequately powered cohorts is needed 
for more definitive understanding of HCM-LVSD.
Conclusions
LVSD develops in ≈8% of patients with HCM and carries 
important clinical implications in that ≈75% of patients 
with HCM-LVSD will experience atrial fibrillation, stroke, 
advanced heart failure (LVEF <35% or NYHA class III/IV), 
appropriate ICD therapy, cardiac transplantation, LVAD 
implantation, or death. However, the natural history 
appears to evolve over a number of years, and indi-
vidual patient experience is variable. Genetic substrate 
appears to play a role in both the risk for developing 
systolic dysfunction and prognosis after systolic dys-
function is present. In addition, patients with HCM with 
an LVEF between 50% and 60% had a nearly 3-fold in-
creased risk of developing systolic dysfunction and may 
benefit from closer clinical surveillance. Further study is 
required to refine clinical predictors of progressive ad-
verse remodeling, especially in patients with prior SRT, 
and to more fully characterize the determinants of clini-
cal outcomes.
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